$ODYY

Odyssey Health, Inc.

CIK:0001626644|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2026	Apr. 30, 2025	Apr. 30, 2026	Apr. 30, 2025
Income Statement [Abstract]
General and administrative expense	$ 297,554	$ 129,055	$ 782,687	$ 865,075
Loss from operations	(297,554)	(129,055)	(782,687)	(865,075)
Loss from change in fair value of Oragenics, Inc. common stock	0	(61,357)	0	(432,053)
Interest expense	(527,551)	(61,395)	(1,035,315)	(193,611)
Financing costs	0	0	(3,080,023)	0
Change in fair value of derivative liability	1,505,581	0	1,503,652	0
Gain on extinguishment of accounts payable	85,369	0	85,369	0
Other income (expense), net	45	64	(10,177)	(36)
Net income (loss) and comprehensive income (loss)	$ 765,890	$ (251,743)	$ (3,319,181)	$ (1,490,775)
Basic net income (loss) and comprehensive income (loss) per share	$ 0.01	$ 0.00	$ (0.03)	$ (0.01)
Diluted net income (loss) and comprehensive income (loss) per share	$ 0.01	$ 0.00	$ (0.03)	$ (0.01)
Shares used for basic net income (loss) comprehensive income (loss) per share	108,031,419	104,709,763	107,299,314	104,709,763
Shares used for diluted net income (loss) comprehensive income (loss) per share	186,674,907	104,709,763	107,299,314	104,709,763

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2026	Apr. 30, 2025
Cash flows from operating activities:
Net loss	$ (3,319,181)	$ (1,490,775)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation	0	108,399
Allowance for research and development rebate due	0	22,625
Financing costs	3,080,023	(0)
Change in fair value of derivative liability	(1,503,652)	0
Amortization of debt discount and closing costs	721,463	43,464
Loss from change in fair value of Oragenics, Inc. common stock	0	432,053
Financing costs paid with issuance of common stock	5,250	0
Gain on extinguishment of accounts payable	(85,369)	0
Changes in operating assets and liabilities:
(Increase) in prepaid expenses and other current assets	(45,334)	(32,234)
Increase (decrease) in accounts payable and accrued wages	(45,452)	189,973
Increase in accounts payable and accrued wages, officers	(3,826)	279,966
Increase in accrued interest	309,300	147,336
Net cash used in operating activities	(886,778)	(299,193)
Cash flows from financing activities:
Proceeds from notes payable	1,165,500	300,000
Net cash provided by financing activities	1,165,500	300,000
Increase in cash and cash equivalents	278,722	807
Cash and cash equivalents:
Beginning of period	19,084	2,379
End of period	297,806	3,186
Supplemental disclosure of cash flow information:
Cash paid for interest	4,552	2,811
Supplemental disclosure of non-cash information:
Common stock issued for conversion of outstanding principal	194,040	0
Common stock issued for conversion of accrued interest and fees	107,350	0
Warrants issued in debt financing	217,581	13,343
Original issue discount on debt and closing costs on notes payable	2,085,771	0
Rent offset payment applied to principal on maintenance note payable	62,680	0
Rent offset payment applied to accrued interest on notes payable	30,492	0
Debt discount recognized on notes payable associated with derivative liability	$ 1,184,943	$ 0

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Apr. 30, 2026	Jul. 31, 2025
Current assets:
Cash	$ 297,806	$ 19,084
Prepaid expenses and other current assets, net	75,973	30,639
Total current assets	373,779	49,723
Total assets	373,779	49,723
Current liabilities:
Accounts payable and accrued wages	1,484,536	1,615,357
Accounts payable and accrued wages, officers	1,854,617	1,858,443
Accrued interest	586,351	421,440
Asset purchase liability	1,125,026	1,125,026
Notes payable, officers and directors	100,000	100,000
Notes payable, net of unamortized debt discounts	2,542,321	1,884,155
Derivative liability	2,430,585	0
Total current liabilities	10,123,436	7,004,421
Commitments and contingencies (Note 3)
Stockholders' deficit:
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding as of April 30, 2026 and July 31, 2025	0	0
Common stock, $0.001 par value, 500,000,000 shares authorized, 100,968,663 and 96,709,763 shares issued and outstanding as of April 30, 2026 and July 31, 2025, respectively	100,969	96,710
Additional paid-in capital	56,214,391	55,694,429
Accumulated deficit	(66,065,017)	(62,745,837)
Total stockholders' deficit	(9,749,657)	(6,954,698)
Total liabilities and stockholders' deficit	$ 373,779	$ 49,723